JPH11510819A - 多発性硬化症の治療 - Google Patents
多発性硬化症の治療Info
- Publication number
- JPH11510819A JPH11510819A JP9529319A JP52931997A JPH11510819A JP H11510819 A JPH11510819 A JP H11510819A JP 9529319 A JP9529319 A JP 9529319A JP 52931997 A JP52931997 A JP 52931997A JP H11510819 A JPH11510819 A JP H11510819A
- Authority
- JP
- Japan
- Prior art keywords
- vitamin
- multiple sclerosis
- compound
- group
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Transplanting Machines (AREA)
- Control Of Vehicles With Linear Motors And Vehicles That Are Magnetically Levitated (AREA)
- Exposure Control For Cameras (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.多発性硬化症の対象の症状を軽減する有効量のビタミンD化合物を投与し、 そして症状の軽減を観察することを含む多発性硬化症の対象の多発性硬化症症状 を治療する方法。 2.前記症状が麻痺症状である請求項1記載の方法。 3.ビタミンD化合物が1α−ヒドロキシ化合物である請求項1記載の方法。 4.前記化合物が1,25(OH)2D3である請求項3記載の方法。 5.投与するビタミンD類化体の量が対象160ポンドにつき1日当り0.5〜 50μgである請求項1記載の方法。 6.投与するビタミンD類化体の量が対象160ポンドにつき1日当り0.5〜 0.75μgである請求項3記載の方法。 7.投与するビタミンD類化体の量が対象160ポンドにつき1日当り3.0〜 10μgである請求項3記載の方法。 8.下記化合物の有効量を多発性硬化症の対象に投与する工程を含む多発性硬化 症の対象の多発性硬化症症状を治療する方法。 (式中、X1およびX2は各々水素およびアシルからなる群から選 択され; Y1およびY2はHであってもよいし、またはその1つがO−アリールもしくは O−アルキルであってβもしくはα配置をとることができ;Z1=Z2=H、また はZ1およびZ2は一緒にCH2であり;そして Rはアルキル基、ヒドロキシアルキル基もしくはフルオロアルキル基であるか 、またはRは下記側鎖を表してもよく: 式中、(a)はSまたはR配置を有してよく、R1は水素、ヒドロキシまたは O−アシルであり、R2およびR3は各々アルキル、ヒドロキシアルキルもしくは フルオロアルキルからなる群から選択され、または一緒になって−(CH2)m− 基を表し、ここでmは2から5までの値を有する整数であり、R4は水素、ヒド ロキシ、フッ素、O−アシル、アルキル、ヒドロキシアルキルおよびフルオロア ルキルからなる群から選択され、R5は水素、ヒドロキシ、フッ素、アルキル、 ヒドロキシアルキルおよびフルオロアルキルからなる群から選択され、またはR4 およびR5は一緒になって二重結合酸素を表し、R6およびR7は一緒になって炭 素−炭素二重結合を形成し、R8はHまたはCH3であってもよく、nは1から5 までの値を有する整数であり、側鎖の20、22または23位のどの位置の炭素 がO、S、またはN原子によって置換されていてもよい。 9.症状が麻痺症状である請求項8記載の方法。 10.前記化合物が1,25−ジヒドロキシビタミンD3、19−ノル−1,2 5−ジヒドロキシビタミンD2、19−ノル−21−エピ−1,25−ジヒドロ キシビタミンD3、1,25−ジヒドロキシ−24−ホモ−22−デヒドロ−2 2E−ビタミンD3、および19−ノル−1,25−ジヒドロキシ−24−ホモ −22−デヒドロ−22E−ビタミンD3の群から選択される請求項8記載の方 法。 11.投与する化合物の量が対象160ポンドにつき1日当り0.5〜50μg である請求項8記載の方法。 12.投与する化合物の量が対象160ポンドにつき1日当り0.5〜0.75 μgである請求項8記載の方法。 13.投与する化合物の量が対象160ポンドにつき1日当り3.0〜10μg である請求項8記載の方法。 14.投与が経口的に行われる請求項8記載の方法。 15.対象が低カルシウム食餌をとっている請求項8記載の方法。 16.投与が夜に行われる請求項8記載の方法。 17.多発性硬化症が疑われる対象に症状を予防する有効量のビタミンD化合物 を投与し、そして症状の軽減を観察することを含む多発性硬化症が疑われる対象 の多発性硬化症症状を予防する方法。 18.前記化合物が1,25(OH)2D3である請求項17記載の方法。 19.下記化合物の有効量を多発性硬化症が疑われる対象に投与する工程を含む 多発性硬化症が疑われる対象の多発性硬化症症状を治療する方法。 (式中、X1およびX2は各々水素およびアシルからなる群から選択され; Y1およびY2はHであってもよいし、またはその1つがO−アリールもしくは O−アルキルでありβもしくはα配置をとることができ;Z1=Z2=H、または Z1およびZ2は一緒にCH2であり;そして Rはアルキル基、ヒドロキシアルキル基もしくはフルオロアルキル基であるか 、またはRは下記側鎖を表してもよく: 式中、(a)はSまたはR配置を有してよく、R1は水素、ヒドロキシまたは O−アシルであり、R2およびR3は各々アルキル、ヒドロキシアルキルもしくは フルオロアルキルからなる群から選択され、または一緒になって−(CH2)m− 基を表し、ここでmは2から5までの値を有する整数であり、R4は水素、ヒド ロキシ、フッ素、O−アシル、アルキル、ヒドロキシアルキルおよびフルオ ロアルキルからなる群から選択され、R5は水素、ヒドロキシ、フッ素、アルキ ル、ヒドロキシアルキルおよびフルオロアルキルからなる群から選択され、また はR4およびR5は一緒になって二重結合酸素を表し、R6およびR7は一緒になっ て炭素−炭素二重結合を形成し、R8はHまたはCH3であってもよく、nは1か ら5までの値を有する整数であり、側鎖の20、22または23位のどの位置の 炭素がO、S、またはN原子によって置換されていてもよい。) 20.前記化合物が、1,25−ジヒドロキシビタミンD3、19−ノル−1, 25−ジヒドロキシビタミンD2、19−ノル−21−エピ−1,25−ジヒド ロキシビタミンD3、1,25−ジヒドロキシ−24−ホモ−22−デヒドロ− 22E−ビタミンD3、および19−ノル−1,25−ジヒドロキシ−24−ホ モ−22−デヒドロ−22E−ビタミンD3の群から選択される請求項19記載 の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/600,913 US5716946A (en) | 1996-02-13 | 1996-02-13 | Multiple sclerosis treatment |
US08/600,913 | 1996-02-13 | ||
PCT/US1996/014253 WO1997029740A1 (en) | 1996-02-13 | 1996-09-05 | Multiple sclerosis treatment |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH11510819A true JPH11510819A (ja) | 1999-09-21 |
JP3701687B2 JP3701687B2 (ja) | 2005-10-05 |
Family
ID=24405578
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP52931997A Expired - Lifetime JP3701687B2 (ja) | 1996-02-13 | 1996-09-05 | 多発性硬化症の治療 |
Country Status (12)
Country | Link |
---|---|
US (1) | US5716946A (ja) |
EP (1) | EP0880350B1 (ja) |
JP (1) | JP3701687B2 (ja) |
KR (1) | KR100347657B1 (ja) |
AT (1) | ATE209483T1 (ja) |
AU (1) | AU6915396A (ja) |
CA (1) | CA2245661C (ja) |
DE (1) | DE69617469T2 (ja) |
DK (1) | DK0880350T3 (ja) |
ES (1) | ES2164916T3 (ja) |
PT (1) | PT880350E (ja) |
WO (1) | WO1997029740A1 (ja) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040043971A1 (en) * | 1995-04-03 | 2004-03-04 | Bone Care International, Inc. | Method of treating and preventing hyperparathyroidism with active vitamin D analogs |
US6242434B1 (en) * | 1997-08-08 | 2001-06-05 | Bone Care International, Inc. | 24-hydroxyvitamin D, analogs and uses thereof |
US20020183288A1 (en) * | 1995-04-03 | 2002-12-05 | Bone Care International, Inc. | Method for treating and preventing hyperparathyroidism |
US7048906B2 (en) | 1995-05-17 | 2006-05-23 | Cedars-Sinai Medical Center | Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions |
US6861053B1 (en) | 1999-08-11 | 2005-03-01 | Cedars-Sinai Medical Center | Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth |
EP1011683A4 (en) * | 1997-05-22 | 2003-06-11 | Cephalon Inc | VITAMIN D ANALOGS AND THEIR EFFECTS ON NEURONS |
US5972917A (en) * | 1998-05-29 | 1999-10-26 | Bone Care Int Inc | 1 α-hydroxy-25-ene-vitamin D, analogs and uses thereof |
CN1148347C (zh) | 1998-05-29 | 2004-05-05 | 骨疗国际公司 | 羟基-25-烯-维生素d类化合物的制备方法 |
US6800287B2 (en) | 1998-09-25 | 2004-10-05 | Yeda Research And Development Co., Ltd. | Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use |
US6479474B2 (en) * | 1999-07-08 | 2002-11-12 | Wisconsin Alumni Research Foundation | Dietary calcium as a supplement to vitamin D compound treatment of multiple sclerosis |
AU6730600A (en) * | 1999-08-27 | 2001-03-26 | Chugai Seiyaku Kabushiki Kaisha | Vitamin d derivatives having substituents at the 2alpha-position |
US6358939B1 (en) | 1999-12-21 | 2002-03-19 | Northern Lights Pharmaceuticals, Llc | Use of biologically active vitamin D compounds for the prevention and treatment of inflammatory bowel disease |
US6989377B2 (en) | 1999-12-21 | 2006-01-24 | Wisconsin Alumni Research Foundation | Treating vitamin D responsive diseases |
US7012086B1 (en) | 2000-06-30 | 2006-03-14 | The Foundation For Innovative Therapies, Inc. | Treatment of retrovirus induced derangements with niacin compounds |
US6894033B2 (en) * | 2001-06-11 | 2005-05-17 | Transition Therapeutics Inc. | Combination therapies using vitamin B12 and therapeutic agents for treatment of viral, proliferative and inflammatory diseases |
US20050175585A1 (en) * | 2001-06-11 | 2005-08-11 | Transition Therapeutics Inc. | Combination therapies using vitamin B12 and interferon for treatment of viral proliferative and inflammatory disesases |
US7658926B2 (en) * | 2001-09-14 | 2010-02-09 | Opexa Pharmaceuticals, Inc. | Autologous T-cell vaccines materials and methods |
SI1459065T1 (sl) * | 2001-12-04 | 2010-11-30 | Teva Pharma | Postopki za merjenje potentnosti glatiramer acetata |
BR0307727A (pt) * | 2002-02-20 | 2005-01-25 | Lilly Co Eli | Fomulação |
KR100795840B1 (ko) * | 2002-08-08 | 2008-01-17 | 베일러 칼리지 오브 메디신 | T세포의 분리 및 식별 |
US7566696B2 (en) * | 2002-09-05 | 2009-07-28 | Wisconsin Alumni Research Foundation | Use of calcitonin and calcitonin-like peptides to treat and prevent multiple sclerosis |
EP3064215A1 (en) * | 2002-10-16 | 2016-09-07 | Samuel F. Hunter | Method for treatment of demyelinating central nervous system disease |
WO2004062620A2 (en) * | 2003-01-13 | 2004-07-29 | Cedars-Sinai Medical Center | Paricalcitol as a chemotherapeutic agent |
US20070037740A1 (en) * | 2003-03-04 | 2007-02-15 | Irit Pinchasi | Combination therapy with glatiramer acetate and alphacalcidol for the treatment of multiple sclerosis |
US20060003950A1 (en) * | 2004-06-30 | 2006-01-05 | Bone Care International, Inc. | Method of treating prostatic diseases using a combination of vitamin D analogues and other agents |
US7094775B2 (en) * | 2004-06-30 | 2006-08-22 | Bone Care International, Llc | Method of treating breast cancer using a combination of vitamin D analogues and other agents |
WO2006032053A2 (en) * | 2004-09-14 | 2006-03-23 | Teva Pharmaceutical Industries, Ltd. | Methods of treating symptoms of multiple sclerosis using vitamin d and related compounds |
JP2008530121A (ja) * | 2005-02-14 | 2008-08-07 | ウイスコンシン アラムナイ リサーチ フオンデーシヨン | 多発性硬化症を治療および予防するためのカルシトニンおよびカルシトニン様ペプチド類の使用 |
US20100003228A1 (en) * | 2006-05-05 | 2010-01-07 | Willimas Jim C | T-cell vaccine |
US20090221538A1 (en) * | 2008-02-01 | 2009-09-03 | Hayes Colleen E | Methods of treating multiple sclerosis by administering pulse dose calcitriol |
US20140296190A1 (en) * | 2013-03-27 | 2014-10-02 | Dsm Ip Assets B.V. | Marketing the use of 25-hydroxyvitamin d3 to enhance cognition |
ES2877568T3 (es) | 2016-02-05 | 2021-11-17 | Orionis Biosciences Nv | Agentes de unión de Clec9A |
US10906985B2 (en) | 2017-02-06 | 2021-02-02 | Orionis Biosciences, Inc. | Targeted engineered interferon and uses thereof |
US11384154B2 (en) | 2017-02-06 | 2022-07-12 | Orionis Biosciences BV | Targeted chimeric proteins and uses thereof |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4279826A (en) * | 1980-09-22 | 1981-07-21 | Wisconsin Alumni Research Foundation | 23,25-Dihydroxyvitamin D3 |
US4307025A (en) * | 1981-02-17 | 1981-12-22 | Wisconsin Alumni Research Foundation | 1α, 25-dihydroxy-2β-fluorovitamin D3 |
US4448721A (en) * | 1982-09-20 | 1984-05-15 | Wisconsin Alumni Research Foundation | Hydroxyvitamin D2 compounds and process for preparing same |
US5036061A (en) * | 1983-05-09 | 1991-07-30 | Deluca Hector F | Process for the preparation of 1 alpha,25-dihydroxylated vitamin D2 and related compounds |
US4500460A (en) * | 1983-08-18 | 1985-02-19 | Wisconsin Alumni Research Foundation | 23,23-Difluoro-25-hydroxy-vitamin D3 and process for preparing same |
US4502991A (en) * | 1983-08-18 | 1985-03-05 | Wisconsin Alumni Research Foundation | 23,23-Difluoro-1α,25-dihydroxy-vitamin D3 |
US4769181A (en) * | 1983-11-07 | 1988-09-06 | Wisconsin Alumni Research Foundation | 1,25-dihydroxyvitamin D2 compounds |
US4505906A (en) * | 1984-01-30 | 1985-03-19 | Wisconsin Alumni Research Foundation | Hydroxyvitamin D2 isomers |
US4588528A (en) * | 1984-05-31 | 1986-05-13 | Wisconsin Alumni Research Foundation | 1,24-dihydroxy-Δ22 -vitamin D3 and process for preparing same |
US4594192A (en) * | 1985-03-20 | 1986-06-10 | Wisconsin Alumni Research Foundation | 2α-fluorovitamin D3 |
US4619920A (en) * | 1985-09-16 | 1986-10-28 | Wisconsin Alumni Research Foundation | 26,26,26,27,27-pentafluoro-1α-hydroxy-27-methoxyvitamin D3 |
JPS63104926A (ja) * | 1986-10-21 | 1988-05-10 | Teijin Ltd | 老年性痴呆症治療又は予防剤 |
CA1333616C (en) * | 1989-03-09 | 1994-12-20 | Hector F. Deluca | 19-nor-vitamin d compounds |
US4973584A (en) * | 1989-03-09 | 1990-11-27 | Deluca Hector F | Novel 1α-hydroxyvitamin D2 epimer and derivatives |
US5260290A (en) * | 1990-02-14 | 1993-11-09 | Wisconsin Alumni Research Foundation | Homologated vitamin D2 compounds and the corresponding 1α-hydroxylated derivatives |
US5030772A (en) * | 1990-02-14 | 1991-07-09 | Deluca Hector F | Process for preparing vitamin D2 compounds and the corresponding 1 α-hydroxylated derivatives |
JP2845342B2 (ja) * | 1990-04-28 | 1999-01-13 | 大正製薬株式会社 | ビタミンd▲下3▼誘導体含有固形製剤組成物 |
US5260199A (en) * | 1991-07-30 | 1993-11-09 | Wisconsin Alumni Research Foundation | Method of producing 1,25-dihydroxyvitamin D3 receptor protein |
ATE144250T1 (de) * | 1991-12-26 | 1996-11-15 | Wisconsin Alumni Res Found | 26,27-dimethylen-1-alpha, 25-dihydroxyvitamin-d2 und 26,27-dihydroxyvitamin-d2 und verfahren zu ihrer herstellung |
AU666529B2 (en) * | 1992-04-24 | 1996-02-15 | Wisconsin Alumni Research Foundation | Method of treating osteoporosis with 1 alpha, 24 (R)-dihydroxy-22 (E)-dehydro-vitamin D3 |
TW272187B (ja) * | 1992-05-20 | 1996-03-11 | Hoffmann La Roche | |
US5371249A (en) * | 1993-05-11 | 1994-12-06 | Wisconsin Alumni Research Foundation | Iodo vitamin D3 compounds and method for preparing same |
US5380720A (en) * | 1993-05-11 | 1995-01-10 | Wisconsin Alumni Research Foundation | Iodo vitamin D3 compounds and method for preparing same |
ES2147238T3 (es) * | 1993-07-09 | 2000-09-01 | Theramex | Nuevos analogos estructurales de la vitamina d. |
US5373004A (en) * | 1993-11-24 | 1994-12-13 | Wisconsin Alumni Research Foundation | 26,28-methylene-1α, 25-dihydroxyvitamin D2 compounds |
US5471382A (en) * | 1994-01-10 | 1995-11-28 | Informed Access Systems, Inc. | Medical network management system and process |
-
1996
- 1996-02-13 US US08/600,913 patent/US5716946A/en not_active Expired - Fee Related
- 1996-09-05 DK DK96929924T patent/DK0880350T3/da active
- 1996-09-05 WO PCT/US1996/014253 patent/WO1997029740A1/en active IP Right Grant
- 1996-09-05 CA CA002245661A patent/CA2245661C/en not_active Expired - Lifetime
- 1996-09-05 DE DE69617469T patent/DE69617469T2/de not_active Expired - Lifetime
- 1996-09-05 AU AU69153/96A patent/AU6915396A/en not_active Abandoned
- 1996-09-05 EP EP96929924A patent/EP0880350B1/en not_active Expired - Lifetime
- 1996-09-05 PT PT96929924T patent/PT880350E/pt unknown
- 1996-09-05 AT AT96929924T patent/ATE209483T1/de active
- 1996-09-05 JP JP52931997A patent/JP3701687B2/ja not_active Expired - Lifetime
- 1996-09-05 KR KR1019980706225A patent/KR100347657B1/ko not_active IP Right Cessation
- 1996-09-05 ES ES96929924T patent/ES2164916T3/es not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
KR100347657B1 (ko) | 2002-11-25 |
DK0880350T3 (da) | 2002-03-25 |
JP3701687B2 (ja) | 2005-10-05 |
AU6915396A (en) | 1997-09-02 |
EP0880350B1 (en) | 2001-11-28 |
PT880350E (pt) | 2002-04-29 |
US5716946A (en) | 1998-02-10 |
EP0880350A1 (en) | 1998-12-02 |
ES2164916T3 (es) | 2002-03-01 |
DE69617469T2 (de) | 2002-07-18 |
CA2245661A1 (en) | 1997-08-21 |
CA2245661C (en) | 2004-02-03 |
WO1997029740A1 (en) | 1997-08-21 |
ATE209483T1 (de) | 2001-12-15 |
KR19990082492A (ko) | 1999-11-25 |
DE69617469D1 (de) | 2002-01-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH11510819A (ja) | 多発性硬化症の治療 | |
Branisteanu et al. | Partial prevention of active heymann nephritis by lα, 25 dihydroxyvitamin D3 | |
Lee et al. | Chronic graft-versus-host disease | |
Ridge et al. | Suppression of experimental allergic encephalomyelitis by mitoxantrone | |
Bouillon et al. | Paracrine role for calcitriol in the immune system and skin creates new therapeutic possibilities for vitamin D analogs | |
Hewison et al. | Vitamin D as a cytokine and hematopoetic factor | |
MXPA02006257A (es) | Uso de compuestos de vitamina d biologicamente activos para la prevencion y tratamiento de enfermedad inflamatoria del intestino. | |
Boshart et al. | Effect of phentolamine on body fat | |
US20100160267A1 (en) | Treatment of Inflammatory Bowel Disease With 2-Methylene-19-Nor-Vitamin D Compounds | |
JP2002511411A (ja) | 抗炎症剤 | |
EP2992881A1 (en) | Pharmaceutical composition for inhibiting immune response through inducing differentiation into regulator t cells and promoting proliferation of regulator t cells | |
US20180021401A1 (en) | Compositions and methods for treatment of intracellular damage and bacterial infection | |
CA2370230C (en) | Treatment of systemic lupus erythematosis | |
Hori et al. | The effects of neurosurgical stress on peripheral lymphocyte subpopulations | |
JP3875730B2 (ja) | 自己免疫疾患の予防治療剤 | |
JP2007523162A (ja) | 2‐メチレン‐19‐ノル‐20(S)‐1α,25‐ジヒドロキシビタミンD3の骨疾患の予防のための使用 | |
Gurbindo et al. | Interleukin-2 activity of colonic lamina propria mononuclear cells in a rat model of experimental colitis | |
CN113209299A (zh) | Ep4受体激动剂和拮抗剂在调控滤泡辅助性t细胞分化中的应用 | |
AU4510001A (en) | Treatment of inflammatory bowel disease with vitamin d compounds | |
US20030188756A1 (en) | Treatment of inflammatory bowel disease with vitamin d compounds | |
Levine et al. | Effect of essential fatty acid deficiency on experimental allergic encephalomyelitis in rats | |
AU2009101279A4 (en) | Medicinal formulation containing selected cytokines | |
Molin et al. | Successful thymopentin treatment of therapy-resistant chronic dermatomycoses | |
Meroni et al. | Improvement of the in vitro immune parameters by thymopentin treatment in aged people | |
Olkowski | The use of thymopoietin (TP-5) in immunodeficiency and malignant diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050426 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20050427 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20050714 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080722 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090722 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090722 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100722 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110722 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110722 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120722 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120722 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130722 Year of fee payment: 8 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |